Statistics from Altmetric.com
Hyperhomocysteinemia increases oxidative stress, a common pathogenic mechanism of injury in chronic kidney disease (CKD) and atherosclerosis.1 Plasma homocysteine has been linked to worsening diabetic nephropathy,2 but no therapeutic trials have assessed the effect of vitamin-based, homocysteine-lowering therapy on slowing the progression of disease. Moreover, hyperhomocysteinemia has been associated with an increased incidence of cardiovascular (CV) disease,3 and participants with impaired kidney function have elevated plasma homocysteine. House and colleagues sought to determine whether B-vitamin therapy reduces progression of CKD and incidence of CV events in participants with diabetic nephropathy.
The DIVINe (Diabetic Intervention with Vitamins to Improve Nephropathy) trial was a multicentre, randomised, double blind study consisting of oral B-vitamin therapy (2.5 mg/day folic acid, 25 mg/day vitamin B6 and 1 mg/day vitamin B12) versus placebo to determine the effect of treatment on the rate of decline of glomerular filtration rate (GFR) over a 36-month period. Two hundred thirty-eight …
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.